Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

The following price predictions are based on a 25 P/E. In the subsequent 5 years to follow, Novo Nordisk’s newest products, ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The ...

不过，Novo Nordisk开发副总裁Martin Holst Lange向分析师表示，他“有信心”更大规模的试验会证明CagriSema能帮助用户减重多达25%。Lange指出，公司基于先前试验的数据得出了这一预测。 Novo Nordisk表示，根据此前的试验，这款新药的安全性和耐受性预计与当前市面上的GLP-1药物相似。

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

In our anniversary episode, we discuss a rare earnings miss for Eli Lilly, a pivotal metabolic dysfunction–associated ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...